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Abstract
Previously, our laboratory showed that interleukin-1
( IL-1) secreted by lipopolysaccharide-activatedmono-
cytes induces promatrilysin expression in the prostate
carcinoma cell line, LNCaP. We now demonstrate that
IL-1- induced promatrilysin expression is mediated by
an indirect mechanism that requires nuclear factor
Kappa B (NFB)-dependent synthesis of IL-6. Inhibition
of protein synthesis with cyclohexamide blocked IL-1-
mediated induction of matrilysin mRNA suggesting that
synthesis of one or more additional factors is required
for IL-1- induced promatrilysin protein expression.
Blockage of NFB transactivation activity abrogated
IL-1- induced promatrilysin expression to baseline
levels suggesting that NFB transactivation activity is
necessary. Inhibition of IL-6 activity attenuated IL-1-
induced promatrilysin, but not NFB transactivation
activity indicating that IL-6 acts downstream of NFB
in potentiation of IL-1-mediated promatrilysin expres-
sion. Inhibition of protein synthesis with cyclohexamide
did not alter IL-6- induced induction of matrilysin mRNA
indicating that, contrary to the mechanism by which IL-
1 regulates promatrilysin expression, IL-6-mediated
matrilysin mRNA expression does not require new
protein synthesis. Transient transfection with dominant
negative STAT3 inhibited IL-1- and IL-6 - induced
promatrilysin. These data provide evidence that NFB-
mediated IL-6 synthesis is required for IL-1- induced
promatrilysin expression, and IL-6 signaling through
STAT3 plays a role in IL-1- induced promatrilysin
expression. Neoplasia (2001) 3, 509–520.
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Introduction
The processes by which tumor cells can invade through the
basal lamina as well as intravasate into the vasculature and
extravasate into surrounding tissues are mediated, in part, by
matrix metalloproteinases (MMPs) [1,2]. MMPs are a family
of secreted zinc-dependent proteolytic enzymes responsible
for degradation of the extracellular matrix [3–5]. MMP
activity has been implicated in matrix degradation during
both normal physiological processes, such as embryonic
development, the cycling endometrium and wound healing,
and pathologic conditions such as cancer. The MMP,
matrilysin (MMP-7, PUMP-1), which, like other MMPs, is
secreted in an inactive form (promatrilysin), is unique in that it
is expressed primarily in glandular epithelial cells. Over-
expression of promatrilysin has been associated with multiple
types of malignancies including gastric, [6 ] esophageal, [7,8]
colon [9], and prostate carcinomas [10,11]. In addition, high
levels of promatrilysin expression have been observed by our
laboratory in inflamed prostatic ducts and glands of the
human acinar prostate [11], cycling endometrial tissues [12],
and in the involuting rat prostate [13].
Previously, our laboratory demonstrated that physiologi-
cally relevant doses of the inflammatory cytokine, interleukin-
1 ( IL-1 ), could induce promatrilysin protein expression up
to 100- fold over baseline expression levels in the prostate
carcinoma cell line, LNCaP [14]. IL-1 stimulates pleiotropic
effects that regulate the acute immune response. Down-
stream effects of IL-1 include stimulation of T cell [15–17]
and B cell [18] proliferation and expression of other signaling
factors such as tumor necrosis factor -, IL -6, and IL-8 [19].
Because of our in vitro finding that IL-1 can induce
promatrilysin expression, we proposed that IL-1 signaling
could also be responsible for the overexpression of proma-
trilysin in inflamed glandular epithelial tissues and prostatic
carcinomas.
Several mechanisms of matrilysin regulation have been
characterized. Induction of matrilysin gene expression by
epidermal growth factor (EGF) and phorbol esters has
previously been attributed to the activity of activator
protein-1 (AP-1) and serum response protein transcription
factors [20]. However, the molecular mechanism(s) involved
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in regulation of IL-1 - induced promatrilysin expression
have not been elucidated.
IL-1 - induced activation of nuclear factor Kappa B
(NFB) has been shown to be involved in regulation of
several other members of the MMP family including MMP-1
and -9 [21–25], as well as other MMPs [26–28]. Further-
more, bothMMP-1 [29] and -9 [30] are known to haveNFB
binding elements residing within the 50 flanking region of their
respective genes. However, contrary to the MMPs that are
known to be regulated by NFB, the sequenced promoter
region of the matrilysin gene does not contain a known
binding element for NFB. However, because IL-1 fre-
quently elicits its downstream effects through NFB trans-
activation activity, we conducted experiments to determine
whether NFB plays a role in IL-1 - induced expression of
promatrilysin in LNCaP cells. We also examined whether the
mechanism of promatrilysin induction by IL-1 is direct,
whereby IL-1 induces NFB-mediated transactivation of
the matrilysin gene independent of synthesis of additional
signaling factors or, indirect, whereby synthesis of one or
more intermediate signaling factors is required. Because
there has been no NFB binding element identified within the
sequenced region of the human matrilysin promoter, we
hypothesized that IL-1 - induced NFB-mediated transcrip-
tion of an intermediate signaling factor(s) is required for
potentiation of promatrilysin expression.
Our laboratory has previously demonstrated that over-
expression of promatrilysin increases invasive capacity of
the prostatic carcinoma cell line, DU-145 [9]. In addition,
Hashimoto et al. [31] showed a significant correlation
between the level of promatrilysin expression and the grade
and stage of prostatic carcinoma, indicating that matrilysin
may play an important role in tumor invasion and metastasis.
These data suggested that control of matrilysin expression
may be a key to preventing prostatic carcinoma progression;
and upstream regulatory factors, including the cytokine, IL-
1, may be useful targets in developing a therapeutic
strategy for treatment of prostate cancer at early stage, to
block invasion and metastases; or at later stage, to prevent
further progression.
Our data have characterized a signal transduction path-
way by which IL-1 regulates promatrilysin expression
through an indirect mechanism requiring NFB-dependent
synthesis of IL-6. This pathway demonstrates, for the first
time, regulation of a MMP by a secreted signaling factor ( IL-
1 ) through an indirect pathway that requires synthesis of an
additional secreted protein ( IL-6). In addition, we show that
STAT3 appears to play a role in the signal transduction
pathway downstream of IL-6.
Materials and Methods
Cell Culture
Lymph node carcinoma cells of the prostate (LNCaP)
were acquired from the American Type Culture Collection
(ATCC, Manasass, VA). LNCaP cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum, 100 g/ml penicillin,
and 100 g/ml streptomycin, both from Gibco-BRL (Rock-
ville, MD).
Cytokines
IL-1 and IL-6 were obtained from Calbiochem (La Jolla,
CA). Cells were serum starved for approximately 16 hours
before cytokine treatment in serum-free DMEM.
Plasmid Constructs
The plasmid construct used in the reporter assays to
measure NFB transactivation activity, NFB-Luc, was
generously provided by the laboratory of Zigang Dong
(University of Minnesota, The Hormel Institute, Austin,
MN). The construct encodes a 196-bp fragment of the HIV
promoter containing 2X NFB binding elements driving a
luciferase reporter gene. The parent vector, PGL2-basic
(Promega, Madison, WI) was used as a control. To generate
the heterologous human matrilysin promoter (HMAT- luc)
construct used in these studies, 1179 bp of the sequenced
human matrilysin promoter (GenBank accession #L22525)
located directly upstream of the TATA box were amplified by
polymerase chain reaction and subcloned into pTAL-Luc
(Promega). Polymerase chain reaction amplification of the
humanmatrilysin promoter (kindly provided by the laboratory
of Lynn Matrisian, Vanderbilt University ) was carried out
using the following heterologous primers, which contained
either Nhe1 (upstream primer or Xho1 (downstream primer)
restriction site sequences linked to matrilysin promoter-
specific sequences (matrilysin-specific sequences are
underlined): upstream primer 50 -CGTCTTGTCATTGGC-
GAATTC-30, and the antisense downstream primer 50 -
CCCCAGTGCAAGTGCAGGTGC-30. The resultant 1217-
bp amplification product was digested with Nhe1/Xho1, gel
purified, and directionally cloned into Nhe1/Xho1-digested
pTAL-Luc vector directly upstream of the thymidine kinase
minimal promoter. The resultant plasmid construct was
confirmed with DNA sequencing. The STAT3 dominant
negative plasmid construct was generously provided by the
laboratory of Ralph A. Bradshaw (University of California
Medical School, Irvine, CA). The double mutant STAT3
contains both Tyr!Phe and Ser!Ala mutations preventing
phosphorylation at sites critical for STAT3 activity [32]. The
parent vector into which the STAT3 double mutant was
cloned, pCMV-1, was used as a control plasmid.
Cationic Lipid Transfection
LNCaP cells were seeded into 12.5 cm2 flasks with
1106 cells per flask, 24 hours before transfection. The
cationic lipid DMRIE-DOPE (Vical Inc., La Jolla, CA) was
used as per standard procedures. Briefly, plasmid DNA
(2.5 g/ flask) and DMRIE-DOPE (10 g/ flasks) were
incubated in a polystyrene tube for 30 minutes. The trans-
fection complex was then added to cells in serum-free
DMEM (1.5ml / flask). Cells remained in transfectionmedium
for approximately 16 hours at which time the cells were
removed from the transfection medium and stimulated with
cytokine under serum-free conditions. For co- transfection
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experiments, 1.25 g of each plasmid was used per flask
such that the total DNA content per flask was 2.5 g. To
ensure consistency of transient transfection efficiency,
LNCaP cells were transfected with pIRES-EGFP (Promega)
and viewed under a fluorescent light microscope to visualize
enhanced green fluorescent protein. Transient transfection
efficiency was consistently reproducible at 20% using these
conditions.
NFB Inhibitors
Sulfasalazine and pyrrolidine dithiocarbamate (PDTC)
were obtained from Sigma Chemical Co. (St. Louis, MI).
LNCaP cells were treated with 0.5 to 1 mM sulfasalazine in
serum-free DMEM, 2 hours before IL-1 stimulation. NFB
SN50 cell -permeable inhibitor and NFB SN50M inactive
control peptide were obtained from Calbiochem (La Jolla,
CA). LNCaP cells were treated with 18 M inhibitory or
control peptide in serum-free DMEM, 1 hour before
stimulation with IL-1.
Quantification of Promatrilysin Expression by ELISA
Sandwich ELISA analyses were performed as described
[14]. The capture antibody (10D2), a mouse monoclonal
antibody, and detection antibody (RB2), a rabbit polyclonal
antibody, were produced by and obtained from the laboratory
of Raymond Nagle (Arizona Cancer Center, Tucson, AZ).
Horseradish peroxidase-conjugated goat anti–rabbit anti-
body (Pierce, Rockford, IL) was used to detect RB2. Purified
promatrilysin was used to generate a standard curve within
the linear range of 0.2 to 12.5 ng/ml.
Quantification of IL-6 Expression by ELISA
Sandwich ELISA analyses were performed by the UMAB
Cytokine Core Laboratory in Baltimore, MD. Conditioned
media samples were diluted and shipped overnight on dry
ice. Human IL-6 wasmeasured by two antibody ELISA using
biotin-streptavidin-peroxidase detection. Cytokine concen-
tration in each sample was calculated from the standard
curve equation. The range of the assay is 1.562 to 200 pg/
ml. A standard curve was generated using concentrations
within this range and an internal control containing 50 pg/ml
was analyzed in parallel.
Measurement of Luciferase
Total protein concentration of each sample was deter-
mined using the DC Bio-Rad Protein Assay (Bio-Rad,
Cambridge, MA). Ten to 30 g of total protein of each sample
was used for the luciferase assays. A TD 20/20 luminometer
(Turner Designs, Pharmingen, San Diego, CA) was used to
quantify the emitted light, which is directly proportional to the
amount of luciferase present in the sample.
Northern Analyses
Total RNA was extracted using RNEasy (Qiagen,
Valencia, CA) 8 to 10 hours following IL-1 or 2 hours
following IL-6 stimulation. Twenty micrograms of total RNA
was subjected to electrophoresis on a 1% agarose, 3- {N -
morpholino}propane-sulfonic acid / formaldehyde gel. The
RNA was transblotted to a nylon membrane (GeneScreen,
NEN Research Products, Boston, MA) and crosslinked with
ultraviolet light (GS Genelinker, Biorad, Hercules, CA). The
membranes were then hybridized with a 32P- labeled random
primed probe generated from cDNA for the mRNA of interest
using the TS RadPrime DNA labeling system (Gibco-BRL,
Gaithersburg, MD) and washed according to the membrane
manufacturer instructions. The membranes were then
exposed to a storage phosphorscreen (Molecular Dynamics,
Sunnyvale, CA). A Molecular Dynamics phosphorimager
equipped with ImageQuant package was used for obtaining
and analyzing digital images. As a control for loading and
transfer of RNA, membranes were stripped by boiling on
0.1% SDS for 30 minutes and reprobed for glyceraldehyde-
30 -phosphate-dehydrogenase (GAPDH) as described with
a probe generated from an 800-bp Xba1-Pst1 fragment
from pHcGAP (ATCC, Rockville, MD).
Results
NFB Mediates IL-1 - Induced Promatrilysin Expression
NFB is known to mediate transcription of IL-1 - induced
genes including the cytokines IL-6 and IL-8 [33]. To
determine whether NFB transactivation activity is neces-
sary for potentiation of IL-1 - induced promatrilysin expres-
sion in LNCaP cells, we used a variety of inhibitors of NFB
activation or nuclear localization to block NFB trans-
activation activity in IL-1 - treated cells. These inhibitors,
which are both known to inhibit activation of NFB, included
the antioxidant and metal chelator, PDTC, as well as
sulfasalazine, a drug commonly prescribed for inflammatory
disorders including ulcerative colitis and rheumatoid arthritis
[34,35]. We also used the NFB SN50 cell -permeable
inhibitor peptide (Calbiochem, San Diego, CA), which
specifically binds to and blocks the nuclear localization site
on the p50 subunit of NFB, thereby inhibiting nuclear
translocation of the active NFB heterodimer following
degradation of IB. The NFB SN50M cell -permeable
inactive control peptide is scrambled and does not have
the ability to bind p50 [36].
We first demonstrated that the inhibitors were effective in
blocking NFB transactivation activity in LNCaP cells using a
luciferase reporter assay. LNCaP cells were transfected with
a plasmid construct encoding a minimal HIV promoter
containing 2X NFB cis elements driving a luciferase
reporter gene. Transfected cells were pretreated with
inhibitor for 1 hour before stimulation with 200 pg/ml IL-
1. Inhibitor concentration remained constant throughout the
duration of IL-1 stimulation. Transcription through NFB cis
elements was determined by quantification of luciferase
expression in whole cell lysates. IL-1 - induced transcription
through NFB cis elements was significantly abrogated by
pretreatment with NFB inhibitors PDTC (Figure 1A, top ),
sulfasalazine (center ), and NFB SN50 cell -permeable
inhibitor peptide (bottom, column 3), but not by NFB
SN50M cell -permeable inactive control peptide (bottom,
column 4).
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Inhibition of NFB transactivation activity also blocked IL-
1 - induced promatrilysin expression (Figure 1B ). Incuba-
tion and treatment times were identical to the preceding
experiment measuring NFB transactivation activity.
Twenty- four hours following IL-1 stimulation, promatrilysin
expression in conditioned media was quantified using ELISA
analyses. In agreement with the pattern observed for
inhibition of transcription through NFB cis elements, IL-
1 - induced promatrilysin expression was blocked by NFB
inhibitors, PDTC (Figure 1B, top ), sulfasalazine (center ),
and NFB SN50 cell -permeable inhibitor peptide (bottom,
column 3), but not by NFB SN50M cell -permeable inactive
control peptide (bottom, column 4).
Cyclohexamide Blocks IL-1 - Induced Matrilysin mRNA
The next step was to determine whether the induction of
promatrilysin expression by IL-1 is indirect and dependent
on synthesis of one or more intermediate signaling factors, or
whether IL-1 acts directly to upregulate promatrilysin
expression in LNCaP cells without synthesis of one or more
intermediate signaling factors. LNCaP cells were concur-
rently treated with cyclohexamide (10 g/ml) and stimulated
with IL-1. Northern analyses for matrilysin messenger RNA
were performed 8 hours after IL-1 stimulation. The 8-hour
time point was used because that is when peak matrilysin
message is observed (data not shown). A strong induction of
matrilysin message was apparent following treatment with
IL-1 alone (Figure 2, lane 1) compared with cells not
stimulated with IL-1 (Figure 2, lane 2). It is of interest that,
although basal promatrilysin expression can be detected at
low levels in LNCaP conditioned media, matrilysin mRNA is
difficult to detect using Northern analyses. Concurrent
treatment with cyclohexamide blocked IL-1 - induced
expression of matrilysin mRNA (Figure 2, lane 3) indicating
a requirement for new protein synthesis for the induction of
promatrilysin expression by IL-1. Inhibition of protein
Figure 1. NFB mediates promatrilysin expression in LNCaP cells. LNCaP cells were transiently transfected with a plasmid construct encoding a minimal HIV
promoter containing 2X NFB binding elements driving a luciferase reporter gene. Transfected cells were treated with either PDTC (125 or 250 nM), sulfasalazine
(0.5 or 1.0 mM), SN50 NFB inhibitory peptide, or SN50B inactive control peptide ( 18 M) 1 hour before stimulation with IL - 1. Twenty - four hours following IL - 1
stimulation, (A ) whole cell lysates were collected and analyzed for luciferase expression and (B ) promatrilysin expression in conditioned media was quantified using
ELISA analyses. The results shown represent the means and standard deviations of three experiments each performed in triplicate.
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synthesis was confirmed by quantification of 35S -methionine
uptake with the dose of cyclohexamide used (data not
shown). Reprobing of the stripped blots for GAPDH mRNA
demonstrated equal loading of RNA samples (Figure 2,
lower panel ).
IL-1 Induces Expression of IL-6 by LNCaP Cells
IL-1 has been shown to induce synthesis of the cytokine
IL-6 through NFB transactivation activity in numerous cell
types [19,37]. In addition, multiple IL-6 responsive con-
sensus elements (NFIL6) have been identified within the
published region of the human matrilysin promoter sequence
[12]. It had previously been established that LNCaP cells do
not constitutively express IL-6 [38]; however, the ability of
IL-1 to induce IL-6 expression in LNCaP cells had not been
tested.
We determined that IL-1 does stimulate high levels of
expression of IL-6 in LNCaP cells. Cells were stimulated with
IL-1, then ELISA analyses were used to quantify IL-1 -
induced IL-6 expression at various time points. IL-1 -
induced IL-6 secretion was substantially increased within
3 hours following stimulation with IL-1, and peaked at
approximately 5 ng/ml (Figure 3 ). The secretion of IL-6
protein induced by IL-1 precedes the IL-1 - induced
increase in matrilysin mRNA expression that begins approx-
imately 4 hours after stimulation and peaks at approximately
8 hours. Inhibition of NFB with sulfasalazine completely
blocked IL-1 - induced expression of IL-6. In addition, p50-
Figure 3. IL - 1 induces expression of IL - 6 in LNCaP cells. LNCaP cells were serum starved for 16 hours then they either remained in serum- free DMEM or were
stimulated with IL - 1 in serum- free DMEM. Conditioned media samples were collected at the indicated time points after IL - 1 stimulation and analyzed for IL -6
concentration using ELISA analyses. Cells stimulated with IL -1 that were pretreated with sulfasalazine ( 1 mM), to inhibit NFB transactivation activity, did not
secrete a measurable amount of IL - 6 ( data not shown ). IL -1 - stimulated cells ( solid bar ) demonstrate induction of IL - 6 expression. The results shown represent
the means and standard deviations of three experiments each performed in triplicate.
Figure 2. Cyclohexamide blocks IL - 1 - induced matrilysin mRNA. LNCaP cells were serum starved for 16 hours then were treated with either 200 pg /ml IL - 1
( lane 1 ), serum- free DMEM ( lane 2 ), or IL - 1 ( 200 pg /ml ) and cyclohexamide (10 g /ml ) simultaneously ( lane 3 ). Total RNA was collected 8 hours following IL -
1 stimulation. RNA samples were subjected to 1% agarose gel electrophoresis and transferred and crosslinked to a nylon membrane. The membrane was probed
for matrilysin mRNA. Blots were stripped and reprobed for GAPDH ( lower panel ). The blot shown is representative of five repeats of this experiment.
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specific peptide also completely abrogated IL-1 expression
of IL-6, and IL-6 levels were not detected at any time point in
cells not stimulated with IL-1 (data not shown).
These data agree with published literature demonstrating
that IL-6 has an inhibitory effect on LNCaP cell growth [39].
IL-6 Induces Promatrilysin Expression in LNCaP Cells
Previous studies have shown that IL-6 induces expres-
sion of several MMPs including MMP-2 and -9 [40]. To
determine whether IL-6 is an intermediate required for
potentiation of IL-1 - induced promatrilysin expression, we
first measured promatrilysin expression in LNCaP cells
treated with escalating dose levels of recombinant IL-6.
Promatrilysin expression in conditioned media were quanti-
fied using ELISA analyses 24 hours following IL-6 stimula-
tion. Our data demonstrate that IL-6 induces promatrilysin
expression in a dose-dependent manner (Figure 4A ). The
induction of promatrilysin with 10 ng/ml recombinant IL-6
was equivalent to the induction observed with 200 pg/ml IL-
1 stimulation. Induction of promatrilysin observed using the
concentration of IL-6 present in medium from IL-1 - treated
cells (5 ng/ml) was approximately 35% less than the level
achieved with IL-1 stimulation.
To determine whether NFB plays a role in IL-6- induced
promatrilysin expression, we quantified NFB transactivation
activity in IL-6-stimulated cells. LNCaP cells were transi-
ently transfected with a plasmid construct encoding a
minimal HIV promoter with 2X NFB cis elements. Trans-
fected cells were stimulated with increasing doses of IL-6.
Luciferase activity in whole cell lysates was quantified
8 hours following cytokine stimulation. IL-6 did not signifi-
cantly induce NFB transactivation activity (Figure 4B ),
indicating that IL-6- induced promatrilysin expression is not
mediated by NFB transactivation activity.
Figure 4. IL -6 induces promatrilysin expression in LNCaP cells. LNCaP cells were transiently transfected with a plasmid construct encoding aminimal HIV promoter
containing 2X NFB binding elements driving a luciferase reporter gene. Transfected cells were treated with escalating doses of recombinant IL -6. Twenty - four
hours following cytokine stimulation, (A ) conditioned media were analyzed for matrilysin expression using ELISA analyses and (B ) luciferase expression in whole
cell lysates was quantified. The results shown represent the means and standard deviations of at least three experiments each performed in triplicate.
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IL-6 Mediates IL-1 - Induced Promatrilysin Expression
We then conducted studies to test whether inhibition of
IL-6 activity could block IL-1 - induced promatrilysin
expression. LNCaP cells were treated with recombinant IL-
1 alone or IL-1 plus either an IL-6 neutralizing antibody
directed against the IL-6 ligand or, to control for a non-
specific antibody effect, an antibody directed against an
unrelated human protein (Nm23). Cells were pretreated with
10 g/ml antibody for 1 hour then, in the presence of
antibody, stimulated with recombinant IL-1 (200 pg/ml) or
IL-6 (5 ng/ml) in serum-free conditions. An additional
10 g/ml of each respective antibody was added to the
media 4 hours subsequent to cytokine stimulation. The dose
of 5 ng/ml recombinant IL-6 was chosen to simulate the
concentration of IL-6 produced by LNCaP cells in response
to treatment with 200 pg/ml IL-1. Using ELISA analyses,
secreted promatrilysin expression in conditioned media was
measured 14 hours following stimulation with either IL-1 or
IL-6 (Figure 5 ). The first column shows the basal level of
promatrilysin expression in the absence of cytokine stim-
ulation. The second and third columns demonstrate the
induction of promatrilysin with 200 pg/ml of IL-1 and 5 ng/
ml IL-6, respectively. As anticipated, the rabbit polyclonal
antibody directed against an unrelated human protein had no
effect on IL-1 - or IL-6- induced promatrilysin expression
(columns 4 and 5). As shown in column 6, IL-6 neutralizing
antibody significantly blocked IL-1 - induced promatrilysin
expression (approximately 60%). Inhibition of IL-6 activity
by the neutralizing antibody was confirmed by demonstrating
virtually complete inhibition of IL-6- induced promatrilysin
expression by the IL-6 neutralizing antibody (column 7).
Higher concentration of IL-6 neutralizing antibody did not
enhance the inhibitory effect (data not shown).
Cyclohexamide Does Not Block IL-6- Induced Matrilysin
mRNA
Similar to the approach taken to characterize the pathway
by which IL-1 induces promatrilysin expression, the next
step was to determine whether the induction of promatrilysin
by IL-6 is indirect, and dependent on synthesis of one or
more intermediate signaling factors, or whether IL-6 acts
directly to upregulate promatrilysin expression in LNCaP
cells without synthesis of one or more intermediate signaling
factors. LNCaP cells were concurrently treated with cyclo-
hexamide (10 g/ml) and stimulated with IL-6. Northern
analyses for matrilysin messenger RNA were performed
2 hours after IL-6 stimulation. The 2-hour time point was
chosen because we observed that matrilysin message
peaked 2 hours following stimulation with IL-6 (data not
shown). A significant induction of matrilysin message was
apparent following treatment with IL-6 alone (Figure 6, lane
2) compared with unstimulated cells. It is of interest that
concurrent treatment of cyclohexamide with IL-6 stimulation
did not block IL-6-mediated transcription of matrilysin
mRNA ( lane 3) indicating that the mechanism by which IL-
6 induces promatrilysin expression is direct and does not
require synthesis of new proteins. Inhibition of protein
synthesis was confirmed by quantification of 35S-methionine
uptake with the dose of cyclohexamide used (data not
shown). Reprobing of the stripped blots for GAPDH mRNA
demonstrated equal loading of RNA samples (Figure 6,
lower panel ).
Figure 5. IL - 6 mediates IL -1 - induced promatrilysin expression. LNCaP cells were serum starved for 16 hours then stimulated with either IL - 1 or IL - 6 in the
presence of 10 g /ml of an antibody against either IL - 6 or an antibody against an unrelated human protein. An additional 10 g /ml of the respective antibody was
added to the medium 4 hours following the first antibody treatment and cytokine stimulation. Using ELISA analyses, promatrilysin expression wasmeasured 10 hours
following IL - 6 stimulation. The results shown represent the means and standard deviations of at least three experiments each performed in triplicate.
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STAT3 Plays a Role in IL-6- Induced Promatrilysin
Expression
We previously showed that transcriptional enhancer
elements present in the human matrilysin promoter region
are responsive to IL-1 [14 ]. We next demonstrated that
transcriptional enhancer elements present in the human
matrilysin promoter region are also responsive to IL-6
stimulation. To study the downstream transcription factor(s)
involved in the induction of matrilysin transcription by IL-1
and IL-6, STAT3 was examined for several reasons. First,
many studies have shown that IL-6 signals directly through
STAT3. For example, Villavicencio et al. [41] demonstrated
that autocrine and paracrine interactions of IL-6 family
cytokines cause STAT3 activation in the angiotensin II
pathway in rat hepatocytes. STAT3 activation has also been
shown to be responsible for IL-6-dependent T cell prolifer-
ation through preventing apoptosis [42]. Furthermore,
Chung et al. [39] and Spiotto and Chung [43,44] have
Figure 7. STAT3 mediates IL - 6 - induced promoter activity. LNCaP cells were transiently co - transfected with a plasmid construct encoding 1.1 kb of the human
matrilysin promoter driving a luciferase reporter gene and, either a plasmid construct encoding a dominant negative STAT3 containing point mutations at critical
phosphorylation sites, or pCMV-1, the parent vector into which the STAT3 double mutant was cloned. Transfected cells were treated with either IL - 1 or IL - 6, then
luciferase activity in whole cell lysates was quantified 24 hours following cytokine stimulation. The results shown represent the means and standard deviations of at
least three experiments.
Figure 6. Cyclohexamide does not block IL -6 - induced matrilysin mRNA. LNCaP cells were serum starved for 16 hours then were treated with either serum free
DMEM ( lane 1 ), 5 ng /ml IL - 6 ( lane 2 ), or IL -6 ( 5 ng /ml ) and cyclohexamide (10 g /ml ) simultaneously ( lane 3 ). Total RNA was collected 2 hours following IL - 1
stimulation. RNA samples were subjected to 1% agarose gel electrophoresis and transferred and crosslinked to a nylon membrane. The membrane was probed for
matrilysin mRNA. Blots were stripped and reprobed for GAPDH ( lower panel ). The blot shown is representative of at least five repeats of this experiment.
516 IL-1-Induced MMP-7 Expression is IL-6 Dependent Maliner -Stratton et al.
Neoplasia . Vol. 3, No. 6, 2001
shown that IL-6 directly activates STAT3, which then
regulates growth inhibition and differentiation in LNCaP
cells. In addition, the published human matrilysin promoter
sequence is known to contain numerous cis elements
including NF-IL6 elements to which STAT3 may be capable
of binding.
LNCaP cells were transiently co- transfected with a
plasmid construct encoding 1.2 kb of the human matrilysin
promoter driving a luciferase reporter gene and, either a
plasmid construct encoding a dominant negative STAT3
containing point mutations at critical phosphorylation sites, or
pCMV-1, the parent vector into which the STAT3 double
mutant was cloned. The ratio of promoter construct to
dominant negative or parent vector was 1:1. Columns 1 and
2 (Figure 7 ) show baseline luciferase activity in unstimulated
cells. Both IL-1 and IL-6 induced activity of the 1.2-kb
human matrilysin promoter as demonstrated by induction of
luciferase activity (columns 3 and 4). It is of interest that the
fold induction of promoter activity achieved with IL-1 versus
IL-6 agrees with the promatrilysin protein expression levels
observed with the respective cytokines as measured by
ELISA analyses shown in Figure 5. Co- transfection with the
STAT3 dominant negative abrogated the fold increase of IL-
1 - induced promoter activity by approximately 45%. In
addition, dominant negative STAT3 inhibited IL-6- induced
promoter activity to baseline levels. These results also
concur with the results presented in Figure 5, where
neutralization of IL-6 inhibited IL-1 - induced promatrilysin
expression by approximately 60%. A higher ratio of dominant
negative STAT3 plasmid to promoter construct (2:1) did not
cause further inhibition of IL-1 - induced matrilysin promoter
activity (data not shown).
Discussion
It has been suggested that the inflammatory response may
play a key role in the development and progression of
prostatic carcinoma. Okada et al. [45] examined inflamma-
tion in needle biopsy specimens in both normal and
carcinoma prostatic tissue to reveal the possible contribution
of histologic inflammation within the prostate to the abnormal
elevation of serum prostate-specific antigen (PSA) levels.
The presence of histologic inflammation within the prostate
was shown to correlate significantly with serum PSA levels
[45]. Histologically defined acute inflammation within the
prostate was found to be a significant contributor to elevated
serum PSA levels. Because of these results, it is now
hypothesized that the assessment of inflammation in needle
biopsy specimens, in conjunction with PSA levels, may be a
useful diagnostic or prognostic indicator for prostatic
carcinoma. Other studies have concurred with these data
[45,46].
Our data demonstrate that IL-1 - induced promatrilysin
expression in LNCaP cells is dependent on NFB-mediated
synthesis of IL-6. In addition, we demonstrate that STAT3
plays a role in the pathway downstream of IL-6. Previously,
using immunohistochemical staining of paraffin-embedded
serial sections of primary prostate tumor tissue, our
laboratory demonstrated that high levels of promatrilysin
were detected adjacent to dilated ducts or atrophic glands
that were surrounded by inflammatory cell infiltrates, which
presumably contain a high concentration of cytokines,
including IL-1 and IL-6 [11]. Subsequently, we showed
that LNCaP cells secrete a high level (70- to 100- fold
increase over baseline expression levels ) of promatrilysin in
response to stimulation with recombinant IL-1. We now
reveal that IL-1 - induced promatrilysin expression is
potentiated through a multi -step pathway that requires
NFB-mediated IL-6 synthesis and downstream signaling
by STAT3.
IL-6 is particularly relevant to prostatic carcinoma for
several reasons. Adler et al. [47] have shown that patients
with metastatic and hormone refractory prostatic carcinoma
have a high level of IL-6 circulating in their peripheral blood.
Furthermore, both IL-6 [48,49] and matrilysin [50] are
known to play a role in differentiation of bone, the tissue to
which prostatic carcinoma characteristically metastasizes,
and circulating levels of IL-6 have been associated with
bone metastasis in patients with prostate carcinoma [47]. In
addition, other studies have demonstrated that the more
progressed and less differentiated hormone- independent
prostatic carcinoma cell lines, PC3 and DU-145, express a
constitutive level of secreted IL-6; however, those data also
showed that the less-progressed and hormone-responsive
LNCaP cells did not secrete any detectable IL-6 [39].
IL-6 has been shown to regulate the expression of
several MMP family members [51,52]. Kossakowska et al.
[40,53] demonstrated that elevated IL-6 expression corre-
lated with upregulation of MMP-2 and -9 in tumor biopsy
specimens from patients with non-Hodgkin’s lymphoma
(NHL). In addition, IL-6 induced expression of MMP-2 and -
9, and significantly upregulated transmigration in the Matrigel
invasion assay by the lymphoid cell lines Raji, Jurkat, and
NC-37 [40,53]. Those data suggested that IL-6 may play a
role in determining aggressiveness of NHL by regulation of
MMP production. In addition, our laboratory demonstrated
that stable transfection of the prostatic carcinoma cell line,
DU-145, with the full - length cDNA of the human matrilysin
gene enhanced invasive capacity of DU-145 cells both in
vitro and in vivo [9 ].
In the initial studies conducted with LNCaP cells, a dose of
200 pg/ml of IL-1 was sufficient to elicit a measurable
induction of promatrilysin [14]. However, this dose was
insufficient for induction of a measurable level of proma-
trilysin by the other cytokines tested, including IL-6. It has
since been determined that IL-6 requires a much higher
concentration (ng/ml range) to elicit its observed down-
stream effects. Interestingly, elevated levels (ng/ml range)
of IL-6 have been shown to be clinically relevant in the
peripheral blood of patients with hormone refractory prostatic
carcinoma [54]. For the first time, we demonstrate that
LNCaP cells have the capacity to secrete IL-6 in response to
IL-1 through a NFB-dependent mechanism.
Research conducted by Okamoto et al. [38] demonstra-
ted that IL-6 is constitutively expressed by the prostatic
carcinoma cell lines, DU-145 and PC3, but not by the
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prostatic carcinoma cell line, LNCaP. It is of interest that IL-
1 and IL-6 have been reported to inhibit the growth of
LNCaP cells, but not DU-145 or PC-3 cells. It is possible
that the inhibitory effect of IL-1 on the growth of LNCaP
cells is mediated by the induction of IL-6 expression in these
cells. Spiotto and Chung [43] have recently determined that
the inhibition of growth in LNCaP cells caused by IL-6 is due
to activation of the STAT3 pathway. Furthermore, they
determined that this pathway is not functional in DU-145 and
PC-3 cells. Is it also of interest that IL-1 has been shown to
inhibit growth and induce neuroendocrine differentiation in
LNCaP cells [55,56].
IL-1 family members and IL-6 may be relevant to cancers
other than prostate carcinoma. Tomimatsu et al. [57] have
shown that the presence of IL-1 and IL-6 in gastric
carcinoma tissues correlated with a more differentiated cell
type within the tumor and with occurrence and recurrence of
liver metastases. In addition, Singh et al. [58 ] have
demonstrated that, of nine melanoma samples examined,
only the most invasive cell line, originally established from a
lymph node metastases, expressed both IL-1 and IL-6, in
addition to other inflammatory cytokines.
We previously determined that IL-1 does not induce
promatrilysin in DU-145 or PC-3 cells (data not shown), and
these cells, which are considered to be more invasive than
LNCaP cells, have no basal expression of promatrilysin,
although they are known to secrete IL-6 constitutively [38].
There is, therefore, a correlation between the ability of IL-6
to induce promatrilysin and the presence of an intact STAT3
pathway. In addition, new protein synthesis is not required for
transcription of matrilysin mRNA by IL-6, and dominant
negative STAT3 inhibited IL-1 - and IL-6- induced matrily-
sin promoter activity. Thus, STAT3 is strongly implicated in
the transcriptional regulation of promatrilysin expression by
IL-6. This suggests that IL-6 downstream signaling through
STAT3 initiates transcription of the matrilysin gene.
In our proposed model (Figure 8 ), NFB is activated in
response to IL-1 ligand binding to its receptor. NFB
subsequently translocates to the nucleus and stimulates
transcription of the IL-6 gene. Once secreted, IL-6 binds to
its receptor, which, in turn, results in activation of STAT3. We
hypothesize that IL-1 - induced expression of promatrilysin
may be regulated by both autocrine and paracrine pathways
of IL-6 ligand binding. Prostatic carcinoma tumors are
Figure 8. Proposed IL -1 - induced promatrilysin expression signaling model.
IL - 1 - induced promatrilysin expression is mediated by synthesis of IL - 6
through a NFB-dependent pathway. In this model, IL - 1 ligand binding to its
receptor initiates the signaling cascade that results in degradation of IB
allowing nuclear translocation of the active NFB heterodimer. Once in the
nucleus, NFB binds cis elements and induces transcription of IL -6 and other
downstream effectors, which, in turn, result in transcription of the matrilysin
gene. IL -6 -mediated promatrilysin expression may be mediated through both
autocrine and paracrine pathways depending on whether the IL - 6 binds to the
IL - 6 receptor on the cell from which it was secreted or binds the IL - 6 receptor
on a neighboring cell that could be of a different type. STAT3 is activated in
response to IL - 6, and dominant negative STAT3 inhibits IL -6 -mediated
promatrilysin expression to baseline levels, which strongly indicates that
STAT3 is involved in transcriptional regulation of IL -1 - and IL - 6 - induced
promatrilysin expression.
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heterogenous in nature; therefore, paracrine signaling
mechanisms may be the most relevant in vivo, and secretion
of a cytokine, like IL-6, or a MMP, like matrilysin, could
potentially elicit multiple effects on the different types of cells
that are present within a tumor. Degradation of the
extracellular matrix by promatrilysin secreted by an epithelial
cell may enhance invasive capacity of neighboring cells.
It is of interest that, although IL-6 appears to be the major
factor responsible for promatrilysin expression in response to
IL-1, these data suggest that an additional signaling
factor(s) may be involved. In our system, approximately
5 ng/ml IL-6 is secreted by LNCaP cells following stimulation
with 200 pg/ml IL-1, and promatrilysin expression is
increased up to 100- fold over baseline expression levels.
However, stimulation with 5 ng/ml of exogenously added
recombinant IL-6 induces only a 50- to 60- fold induction of
promatrilysin. Furthermore, concurrent treatment of LNCaP
cells with IL-1 and IL-6 neutralizing antibody reduces IL-
1 - induced promatrilysin by 50% to 60%, not to baseline
expression levels. Inhibition of IL-1 - and IL-6- induced
matrilysin promoter activity by dominant negative STAT3
agreed with the levels of inhibition observed with the IL-6
neutralizing antibody. Thus, IL-1 may induce one or more
factors in addition to IL-6 that upregulate promatrilysin
expression, and the total induction of promatrilysin observed
on stimulation with IL-1 could be the result of an additive or
synergistic effect of multiple factors. However, because
inhibition of NFB transactivation activity completely abro-
gated IL-1 - induced promatrilysin expression, the other
factor(s) involved must also be regulated by NFB.
Induction of matrilysin gene expression by factors includ-
ing EGF and phorbol esters is attributable to AP-1 and other
serum response factor - regulated transcription factors [20].
However, until now, the pathway by which the inflammatory
cytokine, IL-1, induces promatrilysin expression has been
uncharacterized. Our data show a novel pathway by which
NFB-mediated synthesis of IL-6 is required for potentiation
of IL-1 -mediated transcription of the matrilysin gene
through STAT3 transactivation activity downstream of IL-6.
These data reveal a novel pathway for MMP regulation.
Examination of paracrine interactions between different cells
types and MMP expression may provide a valuable model to
help elucidate invasive and metastatic mechanisms that
occur in vivo in cancer progression that could lead to
identification of novel therapeutic targets including signaling
factors upstream of MMPs, including IL-1 and IL-6.
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